TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015
Summary
Global Markets Direct’s, ‘TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the TaiGen Biotechnology Co., Ltd.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of TaiGen Biotechnology Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of TaiGen Biotechnology Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TaiGen Biotechnology Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the TaiGen Biotechnology Co., Ltd.’s pipeline products
Reasons to buy- Evaluate TaiGen Biotechnology Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TaiGen Biotechnology Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TaiGen Biotechnology Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TaiGen Biotechnology Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TaiGen Biotechnology Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of TaiGen Biotechnology Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
- TaiGen Biotechnology Co., Ltd. Snapshot
- TaiGen Biotechnology Co., Ltd. Overview
- Key Information
- Key Facts
- TaiGen Biotechnology Co., Ltd. - Research and Development Overview
- Key Therapeutic Areas
- TaiGen Biotechnology Co., Ltd. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- TaiGen Biotechnology Co., Ltd. - Pipeline Products Glance
- TaiGen Biotechnology Co., Ltd. - Late Stage Pipeline Products
- Pre-Registration Products/Combination Treatment Modalities
- Phase III Products/Combination Treatment Modalities
- TaiGen Biotechnology Co., Ltd. - Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- TaiGen Biotechnology Co., Ltd. - Early Stage Pipeline Products
- Discovery Products/Combination Treatment Modalities
- TaiGen Biotechnology Co., Ltd. - Drug Profiles
- nemonoxacin
- Product Description
- Mechanism of Action
- R&D Progress
- burixafor
- Product Description
- Mechanism of Action
- R&D Progress
- furaprevir
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules for Gram-Negative Bacterial Infections
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules for Influenza
- Product Description
- Mechanism of Action
- R&D Progress
- TaiGen Biotechnology Co., Ltd. - Pipeline Analysis
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Target
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Route of Administration
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Molecule Type
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action
- TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates
- TaiGen Biotechnology Co., Ltd. - Dormant Projects
- TaiGen Biotechnology Co., Ltd. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- TaiGen Biotechnology Co., Ltd., Key Information
- TaiGen Biotechnology Co., Ltd., Key Facts
- TaiGen Biotechnology Co., Ltd. - Pipeline by Indication, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015
- TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015
- TaiGen Biotechnology Co., Ltd. - Pre-Registration, 2015
- TaiGen Biotechnology Co., Ltd. - Phase III, 2015
- TaiGen Biotechnology Co., Ltd. - Phase II, 2015
- TaiGen Biotechnology Co., Ltd. - Phase I, 2015
- TaiGen Biotechnology Co., Ltd. - Discovery, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Target, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Route of Administration, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Molecule Type, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
- TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates, 2015
- TaiGen Biotechnology Co., Ltd. - Dormant Developmental Projects,2015
- TaiGen Biotechnology Co., Ltd., Subsidiaries
- List of Figures
- TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Indication, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015
- TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Target, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
- TaiGen Biotechnology Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015